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Abstract
Assays for the detection of the iron regulatory hormone hepcidin in plasma or urine have not yet been widely available,
whereas quantitative comparisons between hepcidin levels in these different matrices were thus far even impossible due to
technical restrictions. To circumvent these limitations, we here describe several advances in time-of flight mass
spectrometry (TOF MS), the most important of which concerned spiking of a synthetic hepcidin analogue as internal
standard into serum and urine samples. This serves both as a control for experimental variation, such as recovery and
matrix-dependent ionization and ion suppression, and at the same time allows value assignment to the measured hepcidin
peak intensities. The assay improvements were clinically evaluated using samples from various patients groups and its
relevance was further underscored by the significant correlation of serum hepcidin levels with serum iron indices in healthy
individuals. Most importantly, this approach allowed kinetic studies as illustrated by the paired analyses of serum and urine
samples, showing that more than 97% of the freely filtered serum hepcidin can be reabsorbed in the kidney. Thus, the here
reported advances in TOF MS-based hepcidin measurements represent critical steps in the accurate quantification of
hepcidin in various body fluids and pave the way for clinical studies on the kinetic behavior of hepcidin in both healthy and
diseased states.
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Introduction
Protein profiling by time-of flight mass spectrometry (TOF MS) is
based on polypeptide enrichment by selective binding to a
(bio)chemical surface prior to TOF MS of retained proteins and
peptides [1]. This technique is widely used to address several
biomedicalquestionsintheproteomics field,e.g.forthediscoveryof
disease related biomarkers in biological fluids [2,3] for protein
interaction studies [4] and for immunoproteomics-based approach-
es [5–7]. Furthermore, TOF MS-based assays have the potential to
simultaneously distinguish and quantify multiple isoforms/variants
of a particular protein/peptide in contrast to most ELISA-based
assays [5,8–11]. In all these application areas, reliable quantification
is imperative. Clinical mass spectrometry assays optimally use
internal standards to correct for recovery, variable ionization and
suppression of the molecule under analysis [12,13].
Hepcidin is a 25-amino acid peptide that is synthesized in
hepatocytes and secreted in the plasma. It binds to the cellular iron
export channel ferroportin and causes its internalization and
degradation [14] thereby decreasing iron efflux from enterocytes
and macrophages into plasmareviewed in ref [15–17]. Increased iron
stores and inflammation induce hepcidin synthesis, whereas suppres-
sion occurs during hypoxia and increased and/or ineffective
erythropoiesis. Furthermore, hepcidin deficiency plays a central role
in the iron loading in hereditary hemochromatosis and thalassemia’s.
Notwithstanding recent progress, much work remains in
defining the role of hepcidin in both healthy and diseased states.
However, to date, few investigative tools are available [15–17].
The development of immunochemical methods based on the
production of specific hepcidin antibodies is difficult due to the
small size of hepcidin (25 amino acids; hepcidin-25 [hepc25]), and
its conservation among animal species, complicating the elicitation
of an immune response in host species. To date, mainly the
antibody-based dotblot assay described by Nemeth et al. has
successfully been used to (semi) quantify hepcidin in urine [18–21].
However, due to its quite laborious procedure, and its unsuitability
for serum, this assay is not optimal for measurements in large
clinical studies. By means of surface enhanced laser desorption/
ionisation (SELDI-)TOF MS technology, we and others were
successful to semi-quantify hepcidin and its isoforms in urine and
serum [9,10,22,23]. Very recently, other serum hepcidin assays
were reported that exploited liquid chromatography tandem mass
spectrometry (LC-MS/MS [24,25]). After protein precipitation
and peptide extraction, a mixture of serum and internal standard
could be analyzed by LC-MS/MS. The use of non-hepcidin
related peptides as internal standard, however, may affect the
accuracy and reproducibility of the hepcidin concentration levels.
Here, we describe an update of the TOF MS hepcidin method
for both serum and urine with considerable improvements on
sensitivity, reproducibility, value assignment and quantitative
PLoS ONE | www.plosone.org 1 July 2008 | Volume 3 | Issue 7 | e2706abilities. This facilitates the exchangeability of studies performed
by the few other available methods to date and provides the long
sought tool to study hepcidin kinetics.
Results
To overcome several of the technical limitations that previously
interfered with the robustness of hepcidin measurements by TOF
MS, we have systematically reconsidered all analytical steps and
made improvements wherever possible. This experimental survey
and the subsequent evaluation of the improvements are described
below, whereas technical details can be found in the Material &
Methods section.
Recovery
Relatively large sample volumes (500 mL) obtained by dilution
of the samples prior to sample preparation resulted in higher
hepcidin peaks compared to our previously reported procedure in
which samples were in a much smaller (5 mL) final volume [10].
This increased recovery of hepcidin is likely ascribed to decreased
sticking of hepcidin with the increase of the (sample volume)/(tube
surface) ratio or to less aggregation with the decrease of the
hepcidin concentration. This updated procedure improved
considerably the sensitivity of the method for the detection of
hepc25 (see below).
Oxidation
In some urinary samples the methionine residue of hepc24
(2673.9 Da) and hepc25 (2789.4 Da) were prone to oxidation (to
[D]THFPICIFCCGCCHRSKCGM-OxCCKT, 2689.9 Da and
2805.4 Da, respectively) at experimental conditions [26]. This
ambient ozone induced oxidation artifact was minimized by
carrying out sample preparation in a nitrogen atmosphere by the
use of an incubator with a nitrogen inlet. Oxidation peaks of
hepcidin in the MS spectra were completely absent in urine
samples prepared under these conditions, whereas they were
clearly visible in some spectra of samples loaded on the arrays in
ambient air (Figure 1A). In our hands methionine oxidation of
serum hepcidin was never observed.
Standard curves
Standard curves of the internal standard hepc24 were
constructed by serially diluting hepc24 (0–20 nM) in tubes with
blank urine and serum to an end volume of 500 mL, immediately
applied to IMAC-Cu
2+ Chips and processed according to protocol
and measured by MS. Linear standard curves were obtained for
Figure 1. SELDI-TOF MS profiles obtained in the different experiments. SELDI-TOF MS profiles of (A) hepidin-24 spiked urine sample
showing next to the expected hepcidin forms also methionine oxidized (Ox) forms of Hepc24 and Hepc25; (B and C) different patient sera and urines,
respectively, spiked with Hepc24 (5 nM into urines and 10 nM into sera). Note, the influence of the serum and urine matrices on the peak height of
the Hepc24 spiked to patient samples; (D and E), blank serum and urine samples spiked with both Hepc24 and Hepc25 (7.5 nM of both hepcidin
forms into urine and 10 nM into serum). Note that the method appears to be more sensitive for Hepc25 than for Hepc24, with an average peak
intensity ratio Hepc24/Hepc25 of 0.693. This is probably due to the absence of a negatively charged aspartic acid residue in Hepc24, which negatively
affects its binding on the IMAC-Cu
2+ protein chip surface. The hepcidin isoforms Hepc20, Hepc22 (only in urine), Hepc24 (synthetic analogue) and
Hepc25 are indicated by arrows.
doi:10.1371/journal.pone.0002706.g001
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2=0.996) and blank
serum (y=4.90x+3.97; R
2=0.994).
Matrix influences
To detect possible matrix influences on the flying behavior in
the mass spectrometer, hepc24 was added to diverse urine and
serum samples from our collection that have been shown to
contain various concentrations of endogenous hepc25 [10]. We
found that when spiked with the same hepc24 concentration,
hepc24 peak intensities were lower for serum compared to urine.
This indicates that the protein-rich serum matrix suppresses the
hepcidin signal, possibly by a high competition for binding sites on
the chip surface. Furthermore, we observed that the recovery of
hepc24 also differs between individual serum or urine samples
(Figure 1B and C), which may be attributed to distinct matrix-
dependent hepcidin ionization efficiencies.
Hepc24/hepc25 ratio
As we aimed to base our quantitative hepc25 concentration
measurement on the level of the hepc25 peak intensity relative to
that of hepc24, we set out to determine the hepc24/hepc25
intensity ratio’s in blank urine and serum samples, that were all
spiked with both compounds in duplicates of 5 different
concentration combinations (Figure 1D and E). Results revealed
no influence of the internal standard hepc24 to the peak height
and position of the human hepc25, making a competition between
hepcidin 24 and 25 for binding to the chip and ionization unlikely.
Notably, the IMAC-Cu
2+ method appears to be more sensitive for
the hepc25 than for the hepc24 analogue, with mean (SD) peak
ratio’s hepc24/hepc25 of 0.709 (0.058, n=10) for serum, and
0.678 (0.071, n=10) for urine, with an average of 0.693 (0.066,
n=20) for both body fluids. The observation of similar ratio’s for
both urine and serum matrices, however, suggests that the
intensity ratio is specimen independent.
Reproducibility
Intra-chip or spot-to spot variation of hepc25 measured for the
urine application ranged from 6.1% at 3.2 nM to 7.3% at 1.2 nM
(n=8). Similarly, precision was also good for the serum
application with a CV of 5.7% at the higher level (4.4 nM,
n=8) and 11.7% at the lower level (1.8 nM, n=8). Comparison of
these CV’s (average value of 7.7%) with a CV of around 12%
obtained previously without internal standard [10] indicates that
the use of an internal standard improved precision of the hepc25
assay, mainly by its ability to correct for differences in spot quality
and instrumental settings.
Lower level of detection (LLOD)
Based on the measured background noise in each MS spectrum
(see Figure 2), the calculated LLOD values of the improved
SELDI-TOF MS assay varied between 0.003–0.037 nM/mmol
creat for urine samples. This detection limit appeared to be lower
than that reported by Nemeth et al. [20] with a detection limit of
0.43 nM/mmol creat (10 ng/mg creat; Table 1). Remarkably, for
serum samples the LLOD ranged from 0.55 and 1.55 nM, which
is a significant improvement from the approximate 22 nM
described for our previous procedures [10] and that of 16 nM
reported by Tomosugi et al [22] in a similar procedure.
Furthermore, it is within the range of the detection limits of
0.3–1.8 nM (1–5 ng/ml) described recently by Murphy et al. [24]
and Murao et al. [25] using more laborious LC-MS/MS
procedures (Table 1).
Clinical evaluation in patient groups
After clinical diagnosis we categorized urine and serum sample
pairs from previous studies [9,10,19,27] into 5 clinical groups of 5
patienteachandquantifiedthehepc25levels afterspikingofhepc24
as internal standard. Urine and serum hepcidin values of the
Figure 2. Effect of the use of an internal standard on the
hepcidin-25 concentrations in urine and serum of selected
clinical populations. Hepc25 concentrations were calculated in nM
based on the known concentration of spiked hepc24 in serum (A) and
urine (B) samples. For serum, hepc24 intensities were corrected for the
background intensity of unspiked samples (hepc24-bl). Note that for
both urine and serum specimens the LLOD depends on the individual
sample matrix and therefore varies between samples. The LLOD was
determined in the 25 human serum and urine samples by using the
background intensities at m/z 2400, 2515, 2846 for serum and at m/z
2299, 2510, 2910, for urine samples, respectively. The detection limit
was defined as the mean+2 SD of these measurements and found be
2.0 peak intensity for serum and 1.76 peak intensity for urine. The lower
level of detection (LLOD) in nM of each individual sample was
determined by incorporating the sample specific hepc24 peak intensity
value and these mean LLOD values in peak int for hepc25 peak at
2789 m/z in the formulas 1 and 2 for urine and serum (see Material and
Methods section). Ctrl, control; LPS, volunteers injected with polysac-
charide (6 h after injection); IDA, iron deficiency anemia; TM,
thalassemia major in various stages of disease; HH, C282Y homozygous
hereditary hemochromatosis patients of various stages of disease; e,
hepcidin concentration; M, sample specific LLOD, the hepcidin
concentration of the sample is then,LLOD.
doi:10.1371/journal.pone.0002706.g002
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Figure 2 illustrates the urine and serum hepc25 levels for the
different categories ofpatients.Infact,the urine and serum hepcidin
values in the (small) patient groups increased progressively from
IDA to inflammation, with intermediate values in controls that
differ from both patients with IDA (serum p=0.10, urine p=0.009)
and inflammation (serum p=0.009, urine p=0.009) (Table 1 and
Figure 2). Note that the hepcidin values of thalassemia and
hemochromatosis patients are not particular informative because of
individual differences in extent of anemia and treatment. The
hepcidin concentration ranges we found for the patient groups are
comparable to the scarce data reported by a few other groups
(Table 1 [18,20–22,24]. Nevertheless, international inter-laboratory
comparisons of accuracy and precision of the hepcidin assays in well
defined and larger samples of patients with the various methods
available to date, are warranted to increase insight and exchange-
ability of the hepcidin results between studies (analogous as
performed previously for non-transferrin-bound-iron [28]).
Correlation with serum iron indices in healthy control
subjects
We evaluated the serum assay by correlating the serum hepcidin
levels with various serum iron indices in 23 volunteers. Sample
characteristics are presented in Table 2. Hb, serum ferritin, and
body iron levels were significantly higher for the males than for the
females, whereas serum iron, transferrin saturation (TS), soluble
transferrin receptor (sTfR) and hepcidin levels were similar for
both sexes. Within the strict selection criteria adopted, serum
ferritin levels in these subjects are anticipated to represent a
reliable measure of body iron [29], especially when considering a
formula that includes the levels of serum transferrin receptor [30].
Indeed, serum hepcidin levels correlated significantly with both
ferritin and estimated body iron stores in the total group and in
men (Figure 3; Table 3). For women this was only significant for
body iron stores. These findings are in agreement with previous
findings on the increase of human hepcidin synthesis by iron stores
[18,22,31,32] and thereby demonstrate the usefulness of the
hepcidin assay in clinical studies.
Fractional excretion of hepcidin
As shown in Table 1, value assignment in the current study
shows for the first time that the urine and serum hepcidin levels
appear to be of a similar magnitude. This suggests that after
filtration, hepcidin is almost completely reabsorbed by the
proximal tubulus, similarly to other small proteins, such as b2-
microglobulin. In fact, estimation of the fractional excretions of
hepcidin from urine-serum control pair samples resulted in a
values between 0–3%, pointing towards a 97% to a nearly 100%
tubular reabsorption of the freely filtered serum hepcidin (Table 4).
Discussion
In this study we have described an updated TOF MS method
for both serum and urine hepcidin with considerable improve-
ments on sensitivity, reproducibility, value assignment and,
importantly, quantitative abilities which are critical to allow the
exchangeability of studies performed by the few other available
methods and to study hepcidin kinetics. Our data clearly
demonstrate the added value of hepc24 as an internal standard
for mass spectrometry as it, once spiked to a sample, controls for
the variation in hepc25 outcome due to differences i) in peptide
recovery during sample preparation, ii) changes in ProteinChip
quality, iii) variable ionization and ion suppression, and iv) changes
in instrumental performance of the mass spectrometer (this study;
our unpublished observations).
A notable finding was the fact that hepc24 and hepc25 showed
different binding characteristics when IMAC-Cu
2+ chips were
used as selective surface for protein binding. Possibly, binding of
hepc24 is impaired because it lacks the amino-terminal aspargine
residue of hepc25 (Material & Methods), which may affect metal
affinity of hepcidin [33]. In this study, however, we decided to
continue measurements with IMAC-Cu
2+ chips to allow compar-
ison with previous work [10] by multiplying the concentration
obtained by equation 1 and 2 (Material & Methods) with the
hepc24/hepc25 ratio as a constant. Importantly, our recent
analyses showed that cation exchange-based enrichment of
hepcidin yielded a hepc24/hepc25 ratio of 1 (data not shown),
which implies that both peptides have similar binding character-
Table 1. Comparison of hepcidin results between recent studies.
Method SELDI SELDI LC/MS-MS Immunodot
reference this report Tomosugi [22] Murphy [24] Nemeth [18,20,21]
urine n nM/mmol creatˆ n nM/mmol creatˆ n n nM/mmol creatˆ
LLOD 0.003–0.037
* n.d. n.d n.p. 0.43
controls 5 0.21–2.14 n.d. n.d. 105 0.43–8.54
IDA 5 ,0.011–0.045 n.d. n.d. 62 60.21–0.30
inflammation 5 2.63–11.8 n.a. n.d. 68 62.56–34.1
serum nn M ˆ nMˆ nMˆ
LLOD 0.55–1.55
# 16 0.36 n.d.
controls
$ 5 ,1.04–6.18 n.a. 10 ,0.36–16.3 n.d.
IDA 5 ,0.71–,1.38 n.d. n.d n.d.
Inflammation 5 12.1–51.4 n.a. n.d. n.d.
Data are presented in ranges as data from the current study do not allow calculation of means and SD’s and the raw data of previous studies are only partially available.
LLOD; Lower limit of detection; n.d., not determined; n.a., not applicable; n.p., not provided.
*exact value depend on the individual urine and the creatinine concentration.
#exact value depend on the individual serum.
ˆconversion factors: nM to mg is 2.789; from nM/mmol creat to ng/mg creat is 23.44.
$in a rigorously defined group of healthy controls (see Table 2) these figures are: n=23, range 0.86–12.43 nM.
doi:10.1371/journal.pone.0002706.t001
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recovery of hepcidin is dependent on the employed chromato-
graphic chemistry for protein binding. Therefore, we strongly
recommend controlling for the hepc24/hepc25 ratio on a regular
basis by incorporating hepc24/hepc25 spiked blanks in future
(updated) measurement protocols.
The most valuable feature of the updated hepcidin assay is the
fact that the combination of selective protein binding with sensitive
mass detection is uniquely capable of accurate quantification of
hepcidin in both serum and urine (see Table 1). Importantly,
inclusion of the internal hepc24 standard corrects for urine/blood
matrix-differences, which up till now strongly affected the measured
hepcidin peak intensities. This allowed for the first time the
calculation of the fractional excretion of hepcidin, which appeared
to be ,3%intheanalyzed serum/urine pairs.Thus, these advances
have paved the way for large (pre)-clinical studies to investigate
tubular reabsorption of hepcidin in various clinical disorders,
especially in anemias that are associated with renal diseases where
hepcidin is predicted to be an important contributor [34].
From a clinical standpoint, the availability of an accurate
quantitative evaluation of serum hepcidin represents a substantial
progress. Previous reports casted doubts on the reliability of
Figure 3. Correlation between serum hepcidin and ferritin.
Serum hepcidin levels in 23 healthy volunteers (Table 2), as determined
by our updated MS method, were correlated with their ferritin levels.
Values were log transformed prior to correlation analysis. Pearson
correlation: 0.6804 (p=0.0004).
doi:10.1371/journal.pone.0002706.g003
Table 2. Characteristics of healthy control subjects.
All Males Females P
n2 3 1 2 1 1
Age (years) 28 (25–31) 30 (26–35) 26 (22–30) 0.093
Hb (g/dl) 14.1 (13.6–14.6) 14.9 (14.5–15.3) 13.2 (12.6–13.8) ,0.0001
Iron (mmol/l) 17.6 (15.2–20.0) 17.1 (14.9–19.3) 18.2 (13.1–23.2) 0.656
Ferritin mg/l) 64.6 (46.1–90.6) 111 (75.9–164) 35.7 (26.5–48.1) ,0.0001
TS% 27 (23–31) 27 (23–32) 27 (20–33) 0.844
sTfR (mg/l) 1.1 (0.9–1.2) 1.1 (0.9–1.2) 1.0 (0.9–1.2) 0.622
Body iron (mg/kg) 0.3 (22.6 to 3.2) 4.72 (1.25 to 8.20) 24.43 (27.27 to 21.59) ,0.0001
Serum hepcidin (nmol/l) 5.3 (3.5–8.3) 7.2 (3.3–16.0) 3.9 (2.7–5.4) 0.139
Data are means with 95% C.I. and p-values of males vs females by t-test. TS, transferrin saturation; sTfR, soluble transferrin receptor.
Body iron stores were calculated on the basis of the logarithm of the concentrations in micrograms of serum transferrin receptor/serum ferritin (TfR/ferritin ratio) and
expressed as milligram per kilogram body weight, as follows: body iron (mg/kg)=2[log(TfR/Ferritin ratio) 22.8229]/0.1207 [30]. Positive values represent the iron
surplus in stores, while negative values represent iron deficit in tissues.
doi:10.1371/journal.pone.0002706.t002
Table 4. Fractional excretion of hepcidin.
Disease n fractional excretion (%) sample
12 3
Ctrl 3 1.0 2.3 0.6
LPS 1 2.0 n.a. n.a
TM 3 0.1 1.0 1.2
HH 3 2.8 2.9 1.6
The fractional excretion (FE) is calculated by: urine hepcidin (nM)6serum creat
(mM)6100/serum hepcidin (nM)6urine creat (mM)61000. n, the number of pairs
for which all data needed to calculate the FE were available. Ctrl, controls; LPS,
volunteers injected with polysaccharide (6 h after injection); TM, thalassemia
major in various stages of disease; HH, C282Y homozygous hereditary
hemochromatosis patients at various stages of disease; tubular reabsorbtion
(%)=100- FE (%).
doi:10.1371/journal.pone.0002706.t004
Table 3. Correlation of serum hepcidin levels with iron
indices in controls with rigorously defined normal iron status.
Iron indices All Males Females
Hb 0.08 20.44 0.01
iron 0.13 0.13 0.37
TS (%) 0.40 0.52 0.42
ferritin 0.68** 0.76** 0.57
sTfR 20.25 20.27 20.45
Body iron 0.72** 0.78** 0.65*
Data are correlation coefficients by Pearson correlation. STfR, soluble transferrin
receptor; TS, transferrin saturation. Hepcidin and ferritin values were log
transformed prior to correlation analysis
*:P,0.05;
**:P ,0.01.
doi:10.1371/journal.pone.0002706.t003
Quantitative Hepcidin Assay
PLoS ONE | www.plosone.org 5 July 2008 | Volume 3 | Issue 7 | e2706determining hepcidin in serum, since it did not correlate well with
either clinical diagnosis or laboratory markers of iron metabolism
[35]. Several explanations for these unexpected discrepancies were
postulated, including a possible too rapid clearance of this small
peptide from circulation, suggesting urinary hepcidin (normalized
to glomerular filtration) as a better estimate of hepcidin production
than single-point assay in serum. The data obtained with the
present updated quantitative method, provide evidence for both
good correlation with iron indices in appropriate controls (Table 3),
and proper detection of peptide variations for diagnostic purposes
(Figure 2). This indicates that we may have now reached a
sufficient level of analytic sensitivity to make that the serum
hepcidin measurements can now be used as a tool in clinical
studies
Altogether, this study shows the potential of high-throughput
TOF MS-based diagnostic assays, especially in the case of small
peptides that are difficult to handle in ELISA-based immunological
approaches. Importantly, MS can provide additional information
on post translational modifications, as exemplified by the discrim-
ination between the hepc20, -22, and/or -25 isoforms in serum and
urine. ‘‘However, it goes without saying that several scientific
questions have to be addressed and further assay improvements
should be established before hepcidin measurements can be
implemented in general clinical laboratories. These issues comprise,
but are not limited to, standardization, mass resolution, healthy
reference values, correspondence serum and urine hepcidin,
influence of potential hepcidin carrier proteins, cross-assay
validation, which are all subject of our ongoing investigations.
Nevertheless, we anticipate that the here described and further
advances in TOF MS-based approaches can be instantaneously
implemented in dedicated laboratories to quantify hepcidin levels in
a broad range of biological specimens and thereby will be valuable
to further unravel the role of this peptide hormone in health and
disease. In this respect, it may be appreciated that future updates of
our quantitative TOF MS hepcidin assay will be posted on the
website ‘‘www.hepcidinanalysis.com’’.
Materials and Methods
Patient samples
Study participants consisted of subjects that were randomly
selected from our sample collection described previously [10], and
additional volunteers with normal iron parameters. Participants of
our previous study included 25 urine-serum sample pairs from 5
healthy volunteers (laboratory personnel and some of their
spouses), 5 hereditary hemochromatosis (HFE C282Y-homozy-
gous) patients (various stage of phlebotomy), 5 iron deficiency
anemia patients, and 5 thalassemia patients treated with chelation
therapy. The patients were recruited by their physicians during
outpatient clinic visits (all in the Radboud University Nijmegen
Medical Centre, Nijmegen, the Netherlands, except for the
thalassemia major patients, who were in Ospedale Sant’Eugenio,
Rome, Italy). Endotoxemia samples (n=5) from volunteers were
obtained as previously described [19]. Hepcidin blank sera and
urines were obtained from a patient with juvenile hemochroma-
tosis due to a novel hemojuvelin mutation that was shown to have
hepcidin levels below the detection limit of the method [36].
Twenty-three additional controls (12 men and 11 women) with
strictly normal iron status were enrolled in Verona as previously
described [23]. Briefly, they were selected among healthy
volunteers participating in a phase II trial at the Centre for
Clinical Research of the Azienda Ospedaliero-Universitaria di
Verona, Italy. At enrollment, they completed a questionnaire with
specific items relevant to iron metabolism (i.e. any history of blood
donations, previous pregnancy, menstrual losses, etc.) and were
evaluated by laboratory studies including complete blood count
(CBC), serum iron, transferrin saturation, ferritin, C-Reactive
Protein, soluble Transferrin Receptor (sTfR), liver function tests,
and creatinine. To be considered as appropriate ‘‘normal
controls’’ for the hepcidin assay by SELDI-TOF-MS, all these
parameters were required to be normal.
Written informed consent was obtained from all study
participants, according to the Declaration of Helsinki. Samples
were collected between December 2005 and June 2007 and stored
at 280uC in aliquots to avoid multiple freeze-thaw cycles.
Hepcidin assays for the current study have been performed
between January and July 2007.
SELDI-TOF MS measurements
Hepcidin measurements by SELDI-TOF-MS were performed
as previously described [10] and updated with i) the use of an
internal standard to allow quantification and value assignments to
urine and serum hepcidin levels, and ii) exploiting a working
volume of 500 mL instead of 20 mL to increase recovery of
hepcidin during sample preparation. In brief, after dissolving the
lyophilized peptide hepcidin 24 (hepc24) in distilled water
(0.5 mM), 5 mLo r1 0mL of the solution was added as an internal
standard to 495 mL urine (5 nM) or 490 mL serum sample
(10 nM), respectively. The feasibility of this procedure was
illustrated by application of a 5 ml-sample to copper-loaded
immobilized metal-affinity capture ProteinChip arrays
(IMAC30-Cu
2+) that binds hepcidin based on its affinity for
Cu
2+ ions. However, also weak cation exchange bead-based
approaches were successfully employed to capture hepcidin
(iso)forms based on their isoelectric point .8 to allow hepcidin
measurements by matrix assisted (MA)LDI TOF MS [10, 37], (our
unpublished observations) . All binding surfaces were equilibrated
and washed with appropriate buffers according to the manufac-
tures instructions (Bio-Rad, Hercules, CA). Subsequent work up,
SELDI-TOF MS instrumental settings, read out and data analysis
are described elsewhere [10], with the addition that protein chip
handling was performed in a nitrogen atmosphere to prevent
methionine oxidation [26]. In previous studies, proteomic
techniques showed that hepc25, hepc22 and hepc20 were present
in urine, whereas only hepc25 and hepc20 were present in serum
[10]. Samples with hepc25 peak heights .55 Int were considered
to be out of the linear range and were diluted with blank serum or
urine from a patient with juvenile hemochromatosis [36].
Internal standard
We choose to include an internal standard in our mass
spectrometry method as this enables to: i) increase the precision,
ii) improve the accuracy by reducing matrix influences and to
control for instrumental settings and, iii) assign a value to hepcidin
concentration. As internal standard we selected hepc24 for the
following reasons: i) TOF MS can clearly distinguish it’s molecular
weight from the endogenous human hepcidin isoforms hepc25,
hepc22 and hepc20, ii) it has similar chromatographic binding and
flying characteristics as the natural hepcidin isoforms and iii) its m/z
position in urine and serum SELDI-profiles is in a region with
relatively few other peaks; e.g. in contrast to the heavy isotopes of
hepc25, hepc24 has a mass that is different from that of methionine
oxidized hepc25. In our experiments we used synthetic human
hepc24 (THFPICIFCCGCCHRSKCGMCCKT, 2673.9 Da,
weight assessment by quantitative amino acid analysis in triplicate)
and human hepc25 (DTHFPICIFCCGCCHRSKCGMCCKT,
2789.4 Da) that were obtained from Peptides International
Incorporated (Louisville, KY). Noteworthy, hepc24 differs from
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absence of the amino-terminal aspargine (D) residue, whereas the
natural occurring hepc22 and hepc20 isoforms lack the amino-
terminal sequences DTH and DTHFP, respectively.
This experimental set up enabled us to assign values to urine
(normalized to urinary creatinine values and reported in nM/
mmol creatinine [creat]) and serum hepc25 (nM), which were
formerly expressed as Mint/mmol creat and Mint/L, respectively
[10]. For this purpose the following equations were applied for
urine (1) and serum (2):
1. [(sample 2789 m/z peak intensity)65 nM/(hepc24 spiked
sample 2673 m/z peak intensity)]/mmol creat
2. (sample 2789 m/z peak intensity)610 nM/(hepc24 spiked
sample 2673 m/z peak intensity– non spiked sample
2673 m/z peak intensity)
For the sera, but not for urines, we occasionally observed minor
peak at the 2673 m/z position of hepc24. Therefore, the serum
protocol was adapted in that the peak intensity of the non-spiked
sample was subtracted from the hepc24 peak of the spiked
samples.
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